Home › Ulcerative Colitis › Florida › Jacksonville
Ulcerative Colitis clinical trials in Jacksonville, FL
4 studies for Ulcerative Colitis are looking for participants at sites in and around Jacksonville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 2
- Digestive Disease Consultants DDCJAX, Orange Park · 12 mi away
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RecruitingPhase 1/2Healthy volunteers welcome
- Xencor Investigative Site, Jacksonville
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
RecruitingPhase 2
- Encore Borland-Groover Clinical Research, Jacksonville
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
- Mayo Clinic Jacksonville, Jacksonville
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- New York City, NY23 studies
- Orlando, FL22 studies
- Miami, FL21 studies
- Houston, TX17 studies
- San Antonio, TX16 studies
- Tyler, TX15 studies
- Tacoma, WA15 studies
- Chicago, IL15 studies
- San Diego, CA15 studies
- Colorado Springs, CO14 studies
- Los Angeles, CA13 studies
- St. Louis, MO13 studies
Other studies in Jacksonville
- Breast Cancer40 studies
- Non-Small Cell Lung Cancer39 studies
- Cancer (all types)29 studies
- Metastatic Cancer28 studies
- Colorectal Cancer27 studies
- Prostate Cancer26 studies
- Obesity25 studies
- Heart Failure21 studies
- Pancreatic Cancer20 studies
- Overweight19 studies
- Multiple Myeloma18 studies
- Lung Cancer17 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.